Market capitalization | $1.23m |
Enterprise Value | $-3.03m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.37 |
P/B ratio (TTM) P/B ratio | 0.50 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-12.73m |
Free cash flow (TTM) Free cash flow | $-8.20m |
Cash position | $4.33m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
1 Analyst has issued a forecast PainReform Ltd:
1 Analyst has issued a forecast PainReform Ltd:
Mar '24 |
+/-
%
|
||
Turnover | - - |
-
|
|
Gross income | -0.02 -0.02 |
0%
0%
|
|
EBITDA | -13 -13 |
33%
33%
|
EBIT (operating result) EBIT | -13 -13 |
32%
32%
|
Net profit | -13 -13 |
33%
33%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
PainReform Ltd. operates as a pharmaceutical company. It develops and markets pharmaceuticals. The firm focuses on developing reformulation of pain therapeutics, PainReform applies its propriety formulation technologies to prolong and enhance efficacy, reduce adverse effects shortening recovery time and reduce the need of augmentation with drugs such as opioids and NSAIDS. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.
Head office | Israel |
CEO | Ilan Hadar |
Employees | 7 |
Founded | 2007 |
Website | www.painreform.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.